Tag: value

New ETF offers direct exposure to a digital asset used by global financial institutions for cross-border payments

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS^® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

EfTEN United Property Fund earned a net profit of 170 thousand euros in May and 1,32 million euros in the first five months of 2025 (compared to 357 thousand euros in the same time last year). In May, the fund made a cash distribution to investors in the amount of 1.47 million euros, or 57-euro cents per unit. As a result, the fund's net asset value (NAV) decreased by 4,4% and was 11,02 euros per unit at the end of May. Without the distribution the NAV of EfTEN United Property Fund would have increased by 0,6% in May.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.